Search
Corbus Pharmaceuticals Holdings Inc
CRBPAdd to Watchlist
7.530USD
-0.210-2.71%
Market hours 09/24, 15:12（ET）
139.53MMarket Cap
LossP/E TTM
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Corbus Pharmaceuticals Holdings Inc in the past month.
Strong Buy
5 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
35.889USD+355.73%
CRBP Analyst Recommendation Trends
In the current month, CRBP has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRBP average Analyst price target in the last month is 35.889.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
5
5
5
4
4
4
5
5
5
5
5
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
10
10
10
10
CRBP Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, CRBP EPS is projected to reach -1.215 in FY2026Q3, following reported EPS of -1.805 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.58
-1.22
-1.26
-1.21
-1.32
Actual
-1.24
-1.23
-1.81
--
--
Surprise
+21.04%
-0.64%
-43.51%
--
--
FAQs
What is Corbus Pharmaceuticals Holdings Inc's expected revenue for the next quarter?
Corbus Pharmaceuticals Holdings Inc's expected revenue is 1.67M.
What is Corbus Pharmaceuticals Holdings Inc's price target?
Analysts forecast that Corbus Pharmaceuticals Holdings Inc's price target is USD 35.89, with the highest forecast at USD 48.00 and the lowest forecast at USD 28.00.
How have Corbus Pharmaceuticals Holdings IncCRBP's recent earnings per share performed?
The market expectation was USD -1.81, while Corbus Pharmaceuticals Holdings IncCRBP's earnings per share (EPS) for the previous quarter was USD -1.23. EPS for the next quarter is expected at USD -1.21.
What is the analyst rating for Corbus Pharmaceuticals Holdings Inc?
Based on the ratings of Corbus Pharmaceuticals Holdings Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.